Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018
November 28, 2017 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex出席第29屆Piper Jaffray醫療保健會議
November 22, 2017 18:10 ET | Athenex, Inc.
紐約水牛城, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX),一家致力於開發、開展與將癌症治療新療法商業化的全球生物製藥公司今天宣佈,於美東時間2017年11月29日星期三下午1時,執行長Johnson Lau將出席在紐約舉行的第29屆Piper Jaffray醫療保健會議。 ...
Athenex to Present at 29th Annual Piper Jaffray Healthcare Conference
November 22, 2017 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
2017年ESMO亞洲大會:Oraxol(口服紫杉醇,Athenex)可以在癌症患者身上達成類似於靜脈注射紫杉醇的暴露量
November 21, 2017 06:36 ET | Athenex, Inc.
紐約水牛城, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Athenex,...
ESMO Asia 2017: Oraxol (oral paclitaxel, Athenex) Can Achieve Similar Exposure to IV Paclitaxel in Cancer Patients
November 20, 2017 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.發佈2017年第三季財報
November 10, 2017 16:07 ET | Athenex, Inc.
Oraxol治療乳癌的第III期臨床試驗第一次期中分析結果令人鼓舞KX-01軟膏治療日光性角化症的第III期臨床試驗開始Athenex製藥部推出奧沙利鉑注射液、硫酸特布他林注射液和酮咯酸氨丁三醇注射液,進一步擴大APD的產品組合2017年第三季度營收為1,400萬美元,年度成長率為149%公司將全年營收預測範圍調高至3,300萬美元至3,500萬美元 紐約水牛城, Nov. 11, 2017 ...
Athenex, Inc. Announces Third Quarter 2017 Results
November 09, 2017 07:00 ET | Athenex, Inc.
Encouraging results of 1st interim analysis of the Oraxol Phase III clinical trial for breast cancerCommencement of the KX-01 ointment Phase III clinical trials for Actinic KeratosisLaunched...
Athenex, Inc. to Report Third Quarter 2017 Earnings Results on November 9, 2017
October 30, 2017 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.將於2017年11月9日報告2017年第三季度盈利結果
October 30, 2017 08:00 ET | Athenex, Inc.
紐約州布法羅, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc.(Nasdaq:ATNX)- 致力於發現、開發和商業化治療癌症和相關疾病的新療法的生物製藥公司 - 今天宣布將於2017年11月9日公佈2017年第三季度盈利結果。該公司將於東部時間2017年11月9日星期四上午9時舉行電話會議和音頻網播。 ...
Athenex宣佈藥品安全監控委員會積極推薦繼續Oraxol第III期計劃
October 05, 2017 13:47 ET | Athenex, Inc.
紐約水牛城, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc.(Nasdaq:ATNX),一家致力於開發、發展與將癌症治療新療法商業化的全球生物製藥公司,今天宣佈Oraxol...